PLEURAL DISEASES MARKET ANALYSIS

The Global Pleural Diseases Market size was valued at US$ 5.01 Bn in 2023 and is expected to reach US$ 8.13 Bn by 2030, growing at a compound annual growth rate (CAGR) of 7.2% from 2023 to 2030.

The global pleural diseases market refers to the market for diagnosing, treating, and managing diseases and conditions related to the pleura, the membrane that covers the lungs and lines the chest cavity. Pleural diseases encompass a range of conditions such as pleurisy, pleural effusion, pneumothorax, mesothelioma, and others. These diseases can cause symptoms like chest pain, difficulty breathing, coughing, and fluid accumulation in the pleural space. The market includes various diagnostic tools, imaging techniques, therapeutic interventions, and supportive care measures aimed at improving patient outcomes and the quality of life. With advancements in medical technology, imaging modalities, and treatment approaches, the global pleural diseases market continues to evolve to provide better diagnostic accuracy, more targeted treatments, and improved patient care.

Global Pleural Diseases Market Regional Insights

• North America: North America is the largest market for global pleural diseases, accounting for a share of over 45% in 2022. North America, particularly the U.S., has a well-developed healthcare system and advanced medical technologies, contributing to a significant share of the global pleural diseases market. The region has a relatively higher prevalence of conditions like mesothelioma, which drives the demand for diagnostic services, therapeutic interventions, and supportive care. Additionally, initiatives for early detection and improved management of global pleural diseases contribute to the market growth in this region.
• Europe: Europe is the second-largest market for global pleural diseases, accounting for a share of over 30% in 2022. Europe is another prominent market for global pleural diseases due to its well-established healthcare infrastructure, advanced diagnostic capabilities, and focus on respiratory health. Countries like the U.K., Germany, and France have comprehensive healthcare systems that enable efficient diagnosis, treatment, and management of global pleural diseases. The region also emphasizes research and development, leading to advancements in therapeutic interventions and improved patient outcomes.
• Asia Pacific: Asia Pacific is the fastest-growing market for global pleural diseases, accounting for a share of over 20% in 2022. The global pleural diseases market is witnessing significant growth in the Asia Pacific region due to a combination of factors. Rapid urbanization, lifestyle changes, and increasing industrialization contribute to a higher incidence of respiratory diseases, including pleural conditions. Countries like China, India, and Japan are investing in improving healthcare infrastructure and access to quality care, leading to increased demand for diagnostic tools and treatment options for global pleural diseases.

Figure 1. Global Pleural Diseases Market Share (%), By Region, 2023

To learn more about this report, request a free sample copy

Analyst’s View

The global pleural diseases market growth is driven by several factors, including an aging population, increasing prevalence of respiratory diseases, growing awareness and early diagnosis of pleural conditions, and advancements in medical technologies. The rising incidence of conditions like mesothelioma, often associated with asbestos exposure, also contributes to the market growth. Additionally, the development of minimally invasive procedures, such as thoracoscopy and pleuroscopy, has improved diagnostic capabilities and reduced the need for more invasive surgeries.

Global Pleural Diseases Market Drivers:

• Increasing Prevalence of Respiratory Diseases: The rising prevalence of respiratory diseases, including global pleural diseases, is a significant driver for the market. Factors such as pollution, occupational hazards, lifestyle changes, and aging populations contribute to the increasing burden of respiratory conditions. Conditions like mesothelioma, and pleural effusion drive the demand for diagnostic services, treatment options, and supportive care in the global pleural diseases market. For instance, in the U.S., an estimated 1.5 million pleural effusions are diagnosed annually, while in developed nations, the estimated prevalence of pleural effusion is 320 instances per 100,000 individuals, according to a 2021 WebMD LLC article.
• Technological Advancements in Diagnostic Tools and Imaging: Technological advancements in diagnostic tools and imaging modalities have improved the accuracy and efficiency of diagnosing global pleural diseases. Innovations such as high-resolution imaging, minimally invasive procedures like thoracoscopy and pleuroscopy, and molecular diagnostic techniques enable earlier detection and more precise diagnosis of pleural conditions. These advancements drive the demand for diagnostic services and support better patient management.
• Focus on Personalized Medicine: There is a growing emphasis on personalized medicine in the field of global pleural diseases. The understanding that different patients may respond differently to treatment has led to the development of targeted therapies and precision medicine This personalized approach, which takes into account individual patient characteristics and disease profiles, drives the development of new treatment options and enhances patient outcomes.
• Increasing Investments in Research and Development: Investments in research and development activities play a crucial role in advancing the understanding of global pleural diseases and developing novel therapies. Pharmaceutical and biotechnology companies, as well as academic and research institutions, are actively involved in exploring new treatment approaches, biomarkers, and diagnostic tools. These investments contribute to the expansion of the Global Pleural Diseases market by bringing new innovations and therapies to the forefront.

 Global Pleural Diseases Market Opportunities:

• Advancements in Minimally Invasive Interventions: There is an opportunity for further advancements in minimally invasive interventions for global pleural diseases. Procedures such as thoracoscopy, pleuroscopy, and image-guided therapies have significantly improved patient outcomes and reduced the need for more invasive surgical procedures. Continued research and development in this area can lead to the development of new techniques and tools that enhance the effectiveness and safety of minimally invasive interventions.
• Emerging Biomarkers and Precision Medicine: The identification of biomarkers associated with global pleural diseases presents an opportunity for precision medicine approaches. Biomarkers can help in early detection, prognosis prediction, and treatment response assessment. Further research and validation of biomarkers specific to different global pleural diseases can enable personalized treatment strategies and targeted therapies, optimizing patient outcomes. For instance, on October 12, 2023, BioCaptiva, develops liquid biopsy technology devices to diagnose and monitoring to detect cancers, announced in partnership with the University of the Highlands and islands and NHS Highland, to evaluate whether its BioCaptis device can isolate cell-free DNA from pleural fluid samples insufficient quantities for downstream DNA analysis for the diagnosis of pleural disease.
• Integration of Artificial Intelligence (AI) and Machine Learning (ML): The application of AI and ML in the diagnosis and management of global pleural diseases holds significant potential. AI algorithms can analyze large volumes of medical data, including imaging scans, patient records, and research findings, to assist in accurate diagnosis, treatment planning, and disease monitoring. The integration of AI and ML technologies into clinical practice can enhance efficiency, improve diagnostic accuracy, and support evidence-based decision-making in the Global Pleural Diseases market.
• Telemedicine and Remote Monitoring: Telemedicine and remote monitoring solutions have gained prominence, especially in the context of respiratory diseases. These technologies enable remote consultations, continuous monitoring of patients, and home-based care, improving access to healthcare services for patients with global pleural diseases. The expansion of telemedicine platforms and remote monitoring tools offers opportunities to enhance patient care, facilitate timely interventions, and provide personalized support for individuals with pleural conditions.

 Global Pleural Diseases Market Trends:

• Increasing Focus on Minimally Invasive Procedures: There is a growing trend towards minimally invasive procedures in the management of global pleural diseases. Minimally invasive interventions, such as thoracoscopy and pleuroscopy, offer advantages such as reduced trauma, shorter hospital stays, and faster recovery times compared to traditional open surgeries. This trend is driven by the desire to improve patient outcomes, enhance patient comfort, and minimize healthcare costs.
• Rising Adoption of Molecular Diagnostics: Molecular diagnostic techniques are gaining traction in the Global Pleural Diseases market. These techniques allow for the detection of specific biomarkers, genetic mutations, and molecular alterations associated with global pleural diseases. The use of molecular diagnostics facilitates early detection, precise diagnosis, prognostic assessments, and personalized treatment strategies. The increasing availability and affordability of molecular diagnostic tools contribute to their growing adoption in the market. For instance, on September 12, 2023, researchers reported at the International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer, that the newly identified biomarkers in mesothelioma patients' exhaled breath may be useful in predicting if they're likely to respond to treatment.
• Emphasis on Multidisciplinary Collaboration: There is a growing recognition of the importance of multidisciplinary collaboration in the management of global pleural diseases. Multidisciplinary teams consisting of pulmonologists, thoracic surgeons, radiologists, pathologists, and other healthcare professionals work together to ensure comprehensive care for patients. This collaborative approach facilitates accurate diagnosis, optimal treatment planning, and shared decision-making, leading to improved patient outcomes.
• Integration of Digital Health Technologies: Digital health technologies are being integrated into the Global Pleural Diseases market to improve patient care and management. Telemedicine, remote monitoring, and mobile applications allow for remote consultations, real-time patient monitoring, and data collection. These technologies enable healthcare providers to deliver personalized care, monitor disease progression, and enhance patient engagement. The COVID-19 pandemic has further accelerated the adoption of digital health solutions in the global pleural diseases market.

 Global Pleural Diseases Market Restraints:

• Limited Awareness and Delayed Diagnosis: A significant restraint in the global pleural diseases market is the limited awareness and delayed diagnosis of global pleural diseases. Many pleural conditions, such as mesothelioma and early-stage pleural effusions, often present with nonspecific symptoms or are asymptomatic in the early stages. This leads to delayed diagnosis, which can affect treatment outcomes and limit the effectiveness of interventions. Lack of public awareness and healthcare professional knowledge about these diseases contribute to the delay in diagnosis.
• Cost of Diagnostic Tools and Treatment: The cost of diagnostic tools and treatment modalities for global pleural diseases can be a restraint, particularly in regions with limited healthcare resources and underfunded healthcare systems. High costs associated with imaging techniques, molecular diagnostics, minimally invasive procedures, and targeted therapies may hinder access to timely and effective care for patients. Affordability barriers can limit the adoption of advanced diagnostic and treatment options, leading to suboptimal patient outcomes.
• Limited Availability of Expertise and Resources: Pleural diseases require specialized expertise and resources for accurate diagnosis and optimal management. However, there may be a limited number of healthcare professionals with expertise in global pleural diseases, especially in regions with a shortage of pulmonologists, thoracic surgeons, and other specialists. Insufficient availability of specialized healthcare centers, diagnostic facilities, and advanced treatment options in certain areas can pose a restraint in delivering timely and comprehensive care to patients.

Recent Developments

New product approvals

• On August 8, 2023, Boston Scientific Corporation, a medical device company, announced it had received U.S. Food and Drug Administration (FDA) approval for the POLARx Cryoablation System. The new system, which is indicated for the treatment of patients with paroxysmal atrial fibrillation (AF).
• On June 14, 2023, Amneal Pharmaceuticals, Inc., a pharmaceutical company, announced the 505(b) (2) New Drug Application (NDA) approval from the U.S. Food and Drug Administration for PEMRYDI RTU. This product is indicated for treating non-squamous non-small cell lung cancer and malignant pleural mesothelioma.
• On March 10, 2023, Merck & Co., Inc., a pharmaceutical company, announced that the Phase 2/3 CCTG IND.227/KEYNOTE-483 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemotherapy met its primary endpoint of overall survival (OS) for the first-line treatment of patients with unresectable advanced or metastatic malignant pleural mesothelioma.
• In February 2021, Bristol Myers Squibb, a pharmaceutical company, announced that the European Commission (EC) has approved Opdivo (nivolumab) plus Yervoy (ipilimumab) for the first-line treatment of adults with unresectable malignant pleural mesothelioma (MPM).

 Research and Development Activities

• In May 2022, Oncotelic Inc., a developer of treatments for rare and orphan indications, including Parkinson Disease and various cancers, announced the clearance of the Phase 2 clinical trial protocol for mesothelioma after filing the protocol to the Food and Drug Administration.
• In April 2022, the study titled “IFN-γ Combined with T Cells in the Treatment of Refractory Malignant Pleural Effusion and Ascites” was registered in ClinicalTrials.gov for Malignant Pleural Effusion
• In September 2021, Bristol Mayer Squibb declared three-year data from the CheckMate -743 trial. As per the clinical trial data, serious adverse reactions occurred in 54% of patients receiving OPDIVO plus YERVOY. The most frequent serious adverse reactions reported in ≥2% of patients were pneumonia, pyrexia, diarrhea, pneumonitis, pleural effusion, dyspnea, acute kidney injury, infusion-related reaction, musculoskeletal pain, and pulmonary embolism.

Figure 2. Global Pleural Diseases Market Share (%), By Diagnostic Tools, 2023

To learn more about this report, request a free sample copy

Top Companies in Global Pleural Diseases Market

• Bristol Myers Squibb
• Merck & Co., Inc.
• GlaxoSmithKline plc
• Boehringer Ingelheim International GmbH
• Sanofi
• AbbVie Inc.
• Braun SE
• Becton, Dickinson and Company
• Bicakcilar
• Biometrix
• Cook Medical
• Grena
• Redax
• Rocket Medical
• Smith Medical 

Definition: Pleural diseases refer to a group of conditions affecting the pleura, which is the thin membrane that lines the lungs and chest cavity. These diseases can include inflammation of the pleura (pleurisy), accumulation of fluid in the pleural space (pleural effusion), presence of air in the pleural space (pneumothorax), and the development of cancer in the pleura (mesothelioma). Pleural diseases can cause symptoms such as chest pain, difficulty breathing, and coughing.